Lapatinib
From Proteopedia
(Difference between revisions)
| Line 32: | Line 32: | ||
! 1921 | ! 1921 | ||
! 11040 | ! 11040 | ||
| - | |- | ||
| - | ! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
| - | ! Sunitinib (Sutent) | ||
| - | ! Sorafenib (Nexavar) | ||
|- | |- | ||
! Dosage (mg) | ! Dosage (mg) | ||
Revision as of 08:42, 6 December 2010
Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1][2][3][4][5] | |||||
|---|---|---|---|---|---|
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | |||
| Tmax (hr) | 8 | 8.3 | |||
| Cmax (ng/ml) | 24.6 | 460 | |||
| Bioavailability (%) | Sunitinib (Sutent) | 29-49 | |||
| Protein Binding (%) | 95 | 99 | |||
| T1/2 (hr) | 83 | 29 | |||
| AUC (ng/ml/hr) | 1921 | 11040 | |||
| Dosage (mg) | 50 | 50 | |||
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | |||
